Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference
February 17 2021 - 8:30AM
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a
pharmaceutical technology company, today announced that Robert F.
Apple, President and Chief Executive Officer, is scheduled to
participate and host investor meetings at the SVB Leerink 10th
Annual Virtual Global Healthcare Conference being held on February
22-26, 2021.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector technology. The
Company has a portfolio of proprietary and partnered commercial
products with several product candidates in various stages of
development, as well as significant strategic alliances with
industry leading pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals
(AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s FDA-approved products include XYOSTED®
(testosterone enanthate) injection, OTREXUP® (methotrexate)
injection for subcutaneous use and Sumatriptan Injection USP, which
is distributed by Teva. The Company also markets NOCDURNA®
(desmopressin acetate) in the U.S., which was licensed from Ferring
Pharmaceuticals.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the Company’s ability to achieve
the 2020 and 2021 full-year revenue guidance; the uncertainty
regarding the duration, scope and severity of the COVID-19 pandemic
and the mitigation measures and other restrictions implemented in
response to the same and the impact on demand for our products, new
patients and prescriptions, future revenue, product supply, and our
overall business, operating results and financial condition;
successful commercialization of NOCDURNA®
in the United States and market acceptance and future
revenue from the same: commercial success
of XYOSTED® and
future revenue from the same; market acceptance of
Teva’s generic epinephrine auto-injector product and future revenue
from the same; whether the FDA will withdraw
marketing approval for AMAG Pharmaceuticals’
Makena® subcutaneous auto
injector following the recent FDA letter seeking withdrawal,
whether AMAG will be granted an appeal hearing and if granted,
whether Makena® will be
successful and future prescriptions, market
acceptance and revenue from the same; Teva’s ability to
successfully commercialize VIBEX®
Sumatriptan Injection USP and the amount of revenue from
the same; future prescriptions and sales of
OTREXUP®; Teva’s ability to
successfully commercialize generic teriparatide in 11 countries in
Europe, Canada and Israel and future revenue from the same,
successful development including the timing and results of the
clinical bridging and Phase 3 clinical trial of the drug device
combination product for Selatogrel with Idorsia Pharmaceuticals and
FDA and global regulatory approvals and future revenue from the
same; FDA approval of Teva’s pending ANDA for generic
Forteo® and future revenue from
the same; the timing and results of the Company’s or its partners’
research projects or clinical trials of product candidates in
development including Pfizer’s undisclosed development product;
actions by the FDA or other regulatory agencies with respect to the
Company’s products or product candidates of its partners; continued
growth in product, development, licensing and royalty revenue; the
Company’s ability to meet loan extension and interest only payment
milestones and the ability to repay the debt obligation to Hercules
Capital; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Tram BuiVice President,
Corporate Communications and Investor
Relations609-359-3016tbui@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024